AZN News
AstraZeneca PLC
$170.08
-$1.98(-1.15%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
2.84M
52W Range
$153.41 - $212.71
Target Price
--
AZN news: the latest AstraZeneca PLC headlines, press releases and market updates, newest first.
Latest AZN News
- AstraZeneca’s QUARTZ Study Shines New Light on Real-World Asthma Rescue ChoicesTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 26, 2026
- AstraZeneca Expands Selumetinib’s Real-World Footprint With New NF1 Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 22, 2026
- AstraZeneca (AZN) Receives a Buy from J.P. MorganTipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- AstraZeneca Builds Real-World Kidney Data in China, Signaling Long-Term Growth FocusTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 21, 2026
- AstraZeneca (AZN) Gets a Buy from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- AstraZeneca Advances Kidney Failure Strategy With New Hemodialysis Drug StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Completes Real‑World Asthma Biologic Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Advances Kidney Failure Strategy With New Hemodialysis Drug StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Completes Real‑World Asthma Biologic Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca (AZN) Receives a Buy from UBSTipRanks Auto-Generated Intelligence Newsdesk · Oct 15, 2026
- AstraZeneca’s Pediatric Nexium Study Moves Toward Data Readout, Supporting Long-Term GI FranchiseTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 13, 2026
- AstraZeneca’s Kazakhstan Breast Cancer Study: Real‑World Data With Quiet but Important Signals for AZNTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?Ran Melamed · Oct 7, 2026
- AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory FocusTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
- AstraZeneca Targets COPD Care Efficiency With Hospital Level Transition Bundle StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
- J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
- Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
- AstraZeneca Advances Fixed-Dose Cholesterol Combo With Completed Phase I Bioavailability StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 28, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AZN | $170.08 | -1.2% | 2.84M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |